
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc. is anticipated to sustain high single-digit organic growth due to a combination of new client acquisitions and contractual price escalators, with a long-term margin target of 20%. Recent financial results have exceeded expectations, and the company's Ignite platform is showing signs of traction, indicating potential for improving profitability. Furthermore, the integration of software with professional services uniquely positions Health Catalyst to enhance client outcomes, suggesting a viable pathway for shareholder value creation despite current market challenges.
Bears say
Health Catalyst's financial outlook is hindered by concerns over declining organic revenue, with expectations of a 2-3% year-over-year decrease in 2026 and 14.3% to 11.9% decline anticipated for the first quarter of 2026, which is notably below consensus estimates. Despite a modest 3Q revenue beat, the company's guidance reflects challenges such as client migrations to a lower-cost platform and the restructuring of less-profitable contracts, which may lead to customer attrition and down-selling. Additionally, economic uncertainty and pressure on health systems could exacerbate adverse purchasing conditions, further impacting the company's financial performance.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares